TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.

Robert J Motzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.